Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

van Leth, F.; Phanuphak, P.; Ruxrungtham, K.; Baraldi, E.; Miller, S.; Gazzard, B.; Cahn, P.; Lalloo, Ug; van der Westhuizen, Ip; Malan, Dr; Johnson, Ma; Santos, Br; Mulcahy, F.; Wood, R.; Levi, Gc; Reboredo, G.; Squires, K.; Cassetti, I.; Petit, D.; Raffi, F.; Katlama, C.; Murphy, Rl; Horban, A.; Dam, Jp; Hassink, E.; van Leeuwen, R.; Robinson, P.; Wit, Fw; Lange, Jma

Published in

Elsevier, The Lancet, 9417(363), p. 1253-1263

DOI: 10.1016/s0140-6736(04)15997-7

Tools

Export citation

Search in Google Scholar

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

Journal article published in 2004 by F. van Leth, P. Phanuphak, K. Ruxrungtham, E. Baraldi, S. Miller, B. Gazzard, P. Cahn, Ug Lalloo, Ip van der Westhuizen, Dr Malan, Ma Johnson, Br Santos, F. Mulcahy, R. Wood, Gc Levi and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving allowed

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study